AGENDA DAY 2

 

Day 2 Oct 11th Veterinary

Dr Nathalie Garcon
08:30

Chair’s opening remarks

Dr Mahesh Kumar
08:40

Maternal immunity: opportunities and challenges within the veterinary landscape

 
  • Discussing its role in vaccination and animal health
  • Where do we stand right now? How can this strategy be effectively implemented?
  • What hurdles need to be overcome?
Nandakumar D Reddy
09:10

Prevention of food borne diseases through vaccination: challenges and opportunities in the global poultry industry

 
  • Economic impact of Foodborne diseases to the Global Poultry Industry
  • Emerging/re-emerging foodborne disease pathogens impacting the Global Poultry Industry  
  • Prevention of Food borne zoonosis through vaccination of Poultry: Challenges and opportunities
Dr Rik Koopman
09:40

Disease prevention in relation to animal welfare

 
  • The importance of risk control, identifying current and predicted risks and addressing how these can be minimised effectively
  • Discussing the industries role when concerning risk control and assessing how the industry can address the current risk control issue
Dr James Brooks
10:10

Development of a Serum Free Medium for Expansion of BHK-21 Cells for Vaccine Production

Cell culture media is a critical driver in the biopharmaceutical production process and peptones are frequently used to enhance performance of production media. BHK-21 is an industrially relevant cell line used for production of various animal health vaccines, such as foot-and-mouth disease and rabies. These cells are typically grown in cell culture media supplemented with serum, which introduces additional costs and variability into the process. Understanding the requirements of the animal-health vaccine market, we have leveraged our expertise in peptones and cell culture media development, to develop a high performance serum-free medium for the expansion of BHK-21 cells for vaccine production
10:40

Morning Break

11:40

Interactive Roundtables

Choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 45 minutes so you can join two discussions in the allotted time. The same roundtables will be run twice back to back.

1. Incorporating “passive immunization” with vaccines – the use of Phage therapies and mABs
Dr Eszter Nagy, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH

2. The significant role of the microbiome in disease prevention, treatment and therapeutic development
Jeff Riley, CEO, Synthetic Biologics, Inc.

3. The regulators relationship with Challenge Studies; yesterday, today and tomorrow
Bruno Speder, Head Clinical Regulatory Affairs, SGS Life Sciences
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

4. Advanced veterinary therapies: stem cells, monoclonal antibodies and bacterial phages for veterinary use     
Dr Rosario Bullido, Head of Veterinary Inmunological Medicines Assessment Unit, AEMPS

5. Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
Senior representative, 3M

6. Vaccines don’t protect, vaccination does
Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover

7. Porcine T lymphocytes – analysis of their response after vaccination
Prof Dr Armin Saalmüller, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

8. Using an autologous vaccine to enhance immunotherapy outcomes and tackle a re-occurring disease within companion animals
Dr Patrick Frayssinet, R&D Director

9. Developing vaccines to emerging diseases and effective use of animal models

Professor Miles W Carroll, Head of Research, Deputy Director, National Infections Service, Public Health England

10. Cell Culture Medium – Challenges and Solutions
Senior representative, BD Biosciences
 
13:10

Networking Lunch & Poster Session

Dr Randolph Seidler
14:40

Manufacturing within the veterinary industry – the future of where it’s going

  • The significance of manufacturing quality control for veterinary vaccine development and vaccine efficacy
  •  New manufacturing technologies to that could potentially be commercially viable, and enable effective and rapid response during outbreaks 
  • Challenges the veterinary vaccine manufacturing is currently facing and steps to overcome these
Glen Gifford
15:10

Prioritising diseases for which vaccines could reduce antimicrobial use in animals

  • Preserving the effectiveness of antibiotics
  • Highlighting the gaps in research and development for vaccine preventable diseases in poultry, swine and fish
  • Preventing further consequences of secondary infections
  • Sharing GMP and quality standards for poultry and swine vaccines and diagnostics
15:45

Networking Break

Dr Artur Summerfield
16:15

The role of omics in veterinary vaccinology: opportunities and challenges 

 
  • How can we exploit omics technology to advance veterinary innovation? 
  • Transcriptomics provide markers for potent adjuvants and vaccine efficacy  
  • Transcriptomics help to identify immunological processes crucial for vaccine-induced immunity 
Dr Marisa Arias Neira
16:45

African Swine Fever –  dealing with what is yet to come

 
  • Addressing epidemiology and the increasing risk of its spread across Europe
  • Developing vaccines to address ASF – where do we stand?
  • Challenges needing to be overcome
17:15

Chair’s closing remarks followed by Meet & Greet with key speakers in the Exhibition Hall

last published: 24/Aug/17 10:15 GMT